Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP645898.RAXJMbvc6mTlsa7N3NULsTGhxOrlRubYCLeNrqRkhpHDM130_assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645898.RAXJMbvc6mTlsa7N3NULsTGhxOrlRubYCLeNrqRkhpHDM130_provenance.
• assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP996107.RAWBRfLICbcMzeJchgI6eRjb03rINx2jemwuffpxYvVtU130_assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP996107.RAWBRfLICbcMzeJchgI6eRjb03rINx2jemwuffpxYvVtU130_provenance.
• NP664526.RAnVvNj6WmxxrJEDitYlMLdpnN0uup0n3HMcEI_H7FHzY130_assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP664526.RAnVvNj6WmxxrJEDitYlMLdpnN0uup0n3HMcEI_H7FHzY130_provenance.
• NP996105.RAqskpr6s9RvReZAemQ25wH5mNWqksvfaNIJkZsd784MM130_assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP996105.RAqskpr6s9RvReZAemQ25wH5mNWqksvfaNIJkZsd784MM130_provenance.
• NP996100.RAFrbdcHThzElNvm_ffMlrJ-y0-9VUjADD5tVzzbmVo4A130_assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP996100.RAFrbdcHThzElNvm_ffMlrJ-y0-9VUjADD5tVzzbmVo4A130_provenance.
• NP996102.RAHEla_udaNo4f4UzmidqG1wUSU2btW0Wkbe8ibqi85d0130_assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP996102.RAHEla_udaNo4f4UzmidqG1wUSU2btW0Wkbe8ibqi85d0130_provenance.
• NP996099.RA0ALjaSvkvtKYFnzqvrIbbVHr9VYTbaON-FXv-ueejCg130_assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP996099.RA0ALjaSvkvtKYFnzqvrIbbVHr9VYTbaON-FXv-ueejCg130_provenance.
• NP996103.RAwz98N4TQzcTgNA5S4Bve6AEKw4PwbAvjvIZTfQsuT-E130_assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP996103.RAwz98N4TQzcTgNA5S4Bve6AEKw4PwbAvjvIZTfQsuT-E130_provenance.
• NP996106.RA2l-9G9UWdUGviySGBC2nWBr_a31hBS4FoN0yeQR9nps130_assertion description "[Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP996106.RA2l-9G9UWdUGviySGBC2nWBr_a31hBS4FoN0yeQR9nps130_provenance.